ADVISORY/OXiGENE, Inc. -Nasdaq, SSE: OXGN- to Present at 3rd Annual MASS Opportunities Investor Conference.Business/Technology Editors & Health/Medical Writers ADVISORY...for Tuesday (Oct. 30) BIOWIRE2K --(BUSINESS WIRE) Who: Bjorn Nordenvall, M.D., Ph.D., Chairman and Chief Executive Officer, and Fred Driscoll, President and Chief Financial Officer. Management will discuss clinical data from the Phase I trials of OXiGENE's lead vascular targeting agent, Combretastatin A4 Prodrug prodrug /pro·drug/ (-drug) a compound that, on administration, must undergo chemical conversion by metabolic processes before becoming an active pharmacological agent; a precursor of a drug. , review third-quarter highlights and outline the Company's strategy to advance its novel vascular targeting technology as a treatment for solid tumor tumor: see neoplasm. cancers and other major diseases characterized by neovascularization. What: The Massachusetts Biotechnology Council's 3rd Annual MASS Opportunities Investor Conference When: 9:40 a.m. Tuesday, October 30 Where: Logan Airport Hilton Hotel, Boston, Massachusetts “Boston” redirects here. For other uses, see Boston (disambiguation). Boston is the capital and most populous city of Massachusetts.[3] The largest city in New England, Boston is considered the unofficial economic and cultural center of the entire New Webcast: http://www.massbio.org/ (Live and archived for one month) About OXiGENE OXiGENE, The Vascular Targeting Company, is the world leader in vascular targeting agents. The Company's vascular targeting technology is designed to destroy existing blood vessels Blood vessels Tubular channels for blood transport, of which there are three principal types: arteries, capillaries, and veins. Only the larger arteries and veins in the body bear distinct names. associated with cancerous tumors, and may have an application in the treatment of certain forms of ocular ocular /oc·u·lar/ (ok´u-lar) 1. of, pertaining to, or affecting the eye. 2. eyepiece. oc·u·lar adj. 1. Of or relating to the eye or the sense of sight. disease. With its flagship family of Combretastatin-based vascular targeting agents, OXiGENE is developing a diverse portfolio of innovative products to combat these conditions. The Company's mission is to in-license new therapeutics therapeutics Treatment and care to combat disease or alleviate pain or injury. Its tools include drugs, surgery, radiation therapy, mechanical devices, diet, and psychiatry. from academic partners, and develop new drugs that will enhance the effectiveness of traditional cancer treatments and to introduce innovative therapies that attack cancer and other diseases. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion